プロフィール詳細

プロジェクトを作成

★★★★★

☆☆☆☆☆

★★★★★

☆☆☆☆☆

Emil K.に依頼

Greece

Clinical research specialist with 10 years+ experience of designing and implementing complex clinical trial projects

プロフィール概要

Expert in clinical trial design, phase II/III infectious diseases research, LMIC settings, risk analysis, and trial project evaluations

専門分野

• ☆ Clinical Trials
• ☆ IRB Applications
• ☆ Clinical Trial Design
• ☆ Patient Recruitment
• ☆ Clinical Trial Site Selection & Monitoring
• ☆ Regulatory Affairs
• ☆ Regulatory Writing
• ☆ Clinical Trial Documentation
• ☆ Clinical Trial Protocol Writing
• ☆ Clinical Study Reports

サービス

• Writing
• Research
• Consulting

Writing Clinical Trial Documentation

Research Scientific and Technical Research

Consulting Healthcare Consulting, Operations Consulting, Scientific and Technical Consulting

職務経験

Project Lead - TB-PRACTECAL Clinical Tial

Médecins Sans Frontières‎

- 現在

Clinical Trial Manager

Medecine Sans Frontiers

10月 2016 - 1月 2021

Trials Network Manager

Blood Cancer UK

3月 2014 - 5月 2016

学歴

Master of Medical Science

University of Sheffield

9月 2006 - 6月 2007

BSc

Sheffield Hallam University

9月 2004 - 5月 2007

認定資格

• ICH-Good clinical practice

  UK NIHR

  3月 2016 - 6月 2024

出版物

JOURNAL ARTICLE

Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, Moodliar R, Dodd M, Solodovnikova V, Liverko I, et al.(2023). Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial . The Lancet. Respiratory medicine.

Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, Solodovnikova V, Liverko I, Moodliar R, Dodd M, et al.(2022). A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis . The New England journal of medicine.

Sweeney S, Berry C, Kazounis E, Motta I, Vassall A, Dodd M, Fielding K, Nyang'wa BT(2022). Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis . PLOS global public health.

Berry C, du Cros P, Fielding K, Gajewski S, Kazounis E, McHugh TD, Merle C, Motta I, Moore DAJ, Nyang'wa BT(2022). TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis . Trials.

Wharton-Smith A, Horter S, Douch E, Gray N, James N, Nyang'wa BT, Singh J, Nusratovna PN, Tigay Z, Kazounis E, et al.(2021). Optimising recruitment to a late-phase tuberculosis clinical trial: a qualitative study exploring patient and practitioner experiences in Uzbekistan . Trials.

PREPRINT

Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis @article{PPR:PPR569730, title = {Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis}, author = {Sweeney S and Berry C and Kazounis E and Motta I and Vassall A and Dodd M and Fielding K and Nyang’wa B}, doi = {10.1101/2022.11.08.22282060} } .

Berry C, du Cros P, Fielding K, Gajewski S, Kazounis E, McHugh TD, Merle C, Motta I, Moore DA, Nyang'wa B(2021). Tb-practecal: Study Protocol for a Randomised, Controlled, Open-label, Phase II-III Trial to Evaluate the Safety and Efficacy of Regimens Containing Bedaquiline and Pretomanid for the Treatment of Adult Patients With Pulmonary Multidrug Resistant Tuberculosis .